The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
Background: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile o...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/1/1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588704384811008 |
|---|---|
| author | Anna-Maria Lazaratos Matthew Dankner Aalya Hamouda Soumaya Labidi Victor Cohen Lawrence Panasci Jennifer E. Friedmann François Patenaude Cristiano Ferrario Mark Basik April A. N. Rose Parvaneh Fallah |
| author_facet | Anna-Maria Lazaratos Matthew Dankner Aalya Hamouda Soumaya Labidi Victor Cohen Lawrence Panasci Jennifer E. Friedmann François Patenaude Cristiano Ferrario Mark Basik April A. N. Rose Parvaneh Fallah |
| author_sort | Anna-Maria Lazaratos |
| collection | DOAJ |
| description | Background: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in heavily pretreated breast cancer patients in real practice. Methods: We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. The outcomes of interest were the overall response rate, overall survival, progression-free survival and grade 4–5 adverse events. Objective responses and PFS were assessed in accordance with RECIST 1.1 criteria. Results: We identified 38 patients treated with TDXd. Of these, 15 patients had classically defined HER2-positive (HER2+) breast cancer, 4 of whom had active central nervous system (CNS) metastases. A total of 23 patients had HER2-low breast cancer, 2 of whom had active CNS disease. Of the 33 patients evaluable for response, 21 (63%) patients had a response to treatment, including three (9%) complete responses. Outcomes were similar between patients with a HER2+ and HER2-low status, as well as in patients with or without CNS metastases. No patients experienced grade 4 or 5 toxicities, and four of thirty-eight patients (10.5%) experienced pneumonitis (two patients with grade 3 pneumonitis, one patient with grade 2 and one patient with grade 1), resulting in TDXd discontinuation for three patients (with steroid administration in two patients). Conclusions: TDXd demonstrates impressive activity with manageable adverse event profiles in this heavily pretreated population that includes patients with active CNS metastases. |
| format | Article |
| id | doaj-art-748a8bc97bed4d90bba26b2333ebb7d1 |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-748a8bc97bed4d90bba26b2333ebb7d12025-01-24T13:28:19ZengMDPI AGCurrent Oncology1198-00521718-77292024-12-01321110.3390/curroncol32010001The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single CentreAnna-Maria Lazaratos0Matthew Dankner1Aalya Hamouda2Soumaya Labidi3Victor Cohen4Lawrence Panasci5Jennifer E. Friedmann6François Patenaude7Cristiano Ferrario8Mark Basik9April A. N. Rose10Parvaneh Fallah11Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3A 1A3, CanadaRosalind and Morris Goodman Cancer Institute, Montreal, QC H3A 1A3, CanadaFaculty of Medicine, McGill University, Montreal, QC H3G 2M1, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital, Montreal, QC H3T 1E2, CanadaBackground: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in heavily pretreated breast cancer patients in real practice. Methods: We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. The outcomes of interest were the overall response rate, overall survival, progression-free survival and grade 4–5 adverse events. Objective responses and PFS were assessed in accordance with RECIST 1.1 criteria. Results: We identified 38 patients treated with TDXd. Of these, 15 patients had classically defined HER2-positive (HER2+) breast cancer, 4 of whom had active central nervous system (CNS) metastases. A total of 23 patients had HER2-low breast cancer, 2 of whom had active CNS disease. Of the 33 patients evaluable for response, 21 (63%) patients had a response to treatment, including three (9%) complete responses. Outcomes were similar between patients with a HER2+ and HER2-low status, as well as in patients with or without CNS metastases. No patients experienced grade 4 or 5 toxicities, and four of thirty-eight patients (10.5%) experienced pneumonitis (two patients with grade 3 pneumonitis, one patient with grade 2 and one patient with grade 1), resulting in TDXd discontinuation for three patients (with steroid administration in two patients). Conclusions: TDXd demonstrates impressive activity with manageable adverse event profiles in this heavily pretreated population that includes patients with active CNS metastases.https://www.mdpi.com/1718-7729/32/1/1trastuzumabderuxtecanTDXdantibody–drug conjugatebreast cancer |
| spellingShingle | Anna-Maria Lazaratos Matthew Dankner Aalya Hamouda Soumaya Labidi Victor Cohen Lawrence Panasci Jennifer E. Friedmann François Patenaude Cristiano Ferrario Mark Basik April A. N. Rose Parvaneh Fallah The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre Current Oncology trastuzumab deruxtecan TDXd antibody–drug conjugate breast cancer |
| title | The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre |
| title_full | The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre |
| title_fullStr | The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre |
| title_full_unstemmed | The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre |
| title_short | The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre |
| title_sort | real world clinical outcomes of heavily pretreated her2 and her2 low metastatic breast cancer patients treated with trastuzumab deruxtecan at a single centre |
| topic | trastuzumab deruxtecan TDXd antibody–drug conjugate breast cancer |
| url | https://www.mdpi.com/1718-7729/32/1/1 |
| work_keys_str_mv | AT annamarialazaratos therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT matthewdankner therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT aalyahamouda therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT soumayalabidi therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT victorcohen therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT lawrencepanasci therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT jenniferefriedmann therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT francoispatenaude therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT cristianoferrario therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT markbasik therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT aprilanrose therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT parvanehfallah therealworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT annamarialazaratos realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT matthewdankner realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT aalyahamouda realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT soumayalabidi realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT victorcohen realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT lawrencepanasci realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT jenniferefriedmann realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT francoispatenaude realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT cristianoferrario realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT markbasik realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT aprilanrose realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre AT parvanehfallah realworldclinicaloutcomesofheavilypretreatedher2andher2lowmetastaticbreastcancerpatientstreatedwithtrastuzumabderuxtecanatasinglecentre |